Asia · Bolsa y Finanzas · Vietnam Investment Review

CSL secures lixudebart licensing deal with Alentis for 355 million dollars

Publicado por Vietnam Investment Review · Vietnam hace 9 h

Biopharmaceutical firm CSL paid 355 million US dollars upfront to Alentis to commercialise lixudebart, pledging up to 1.2 billion US dollars in milestone payments for rare disease…

Leer el artículo completo en Vietnam Investment Review Inicie sesión para guardar

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (vir.com.vn)

CSL secures lixudebart licensing deal with Alentis for 355 million dollars

También te puede interesar

รัฐบาลดึง ‘เนเน่’ แขกพิเศษ นายกฯ โชว์พลังเสียงต้อนรับ 400 ผู้นำการเงินโลก

DBS tops trades in smaller board lots on debut of revised SGX framework

Selected 11 stocks see immediate uptake of smaller board lot sizes on SGX

Sensex Today | Stock Market Highlights: Market ends higher for 2nd straight day; Nifty reclaims 22,700

Why Kotak Mahindra Bank shares are outperforming Nifty 50 and Bank Nifty in the last two months? Experts explain

More about the Nobel prize winner in Physics

CSL secures lixudebart licensing deal with Alentis for 355 million dollars

Compartir

También te puede interesar

รัฐบาลดึง ‘เนเน่’ แขกพิเศษ นายกฯ โชว์พลังเสียงต้อนรับ 400 ผู้นำการเงินโลก

DBS tops trades in smaller board lots on debut of revised SGX framework

Selected 11 stocks see immediate uptake of smaller board lot sizes on SGX

Sensex Today | Stock Market Highlights: Market ends higher for 2nd straight day; Nifty reclaims 22,700

Why Kotak Mahindra Bank shares are outperforming Nifty 50 and Bank Nifty in the last two months? Experts explain

More about the Nobel prize winner in Physics